Background: Conventional phase I algorithms for finding a phase-2 recommended dose (P2RD) based on toxicity alone is problematic because the maximum tolerated dose (MTD) is not necessarily the optimal dose with the most desirable riskbenefit trade-off. Moreover, the increasingly common practice of treating an expansion cohort at a chosen MTD has undesirable consequences that may not be obvious.
Introduction
The primary objective of a conventional phase I oncology trial is to establish a phase-II recommended dose (P2RD), which is commonly done by performing dose escalation up to the maximal tolerated dose (MTD) using adaptive designs such as 3 þ 3 algorithms [1] and the continuous reassessment method (CRM) [2] . Most phase I trials are small, with very few patients treated at the MTD, often 6 or 9. To obtain more reliable toxicity estimates, and collect efficacy data, phase I trials often include 'expansion cohorts' that treat additional patients at the MTD. In the sequel, by 'efficacy' we mean a desirable clinical outcome, which may be a composite of several events that can be scored soon enough after dose administration for adaptive decision making to be done feasibly. This includes the special case of 'activity', such as >50% shrinkage of a solid tumor, engraftment of a stem cell transplant, or resolution of an infection. Here, 'efficacy' is not used to denote a long-term end point, such as overall survival or progress free survival, commonly used in phase III trials.
The traditional phase I paradigm of determining a P2RD based on toxicity with a small sample size, without using efficacy in the dose-finding algorithm, has some undesirable consequences. escalating from d ¼ 3 to d ¼ 4 increases the toxicity probability from p T (3) ¼ 0.20 to p T (4) ¼ 0.30, but doubles the efficacy probability, from p E (3) ¼ 0.30 to p E (4) ¼ 0.60. This small increase in toxicity may be a reasonable trade-off for the large increase in efficacy by choosing d ¼ 4 rather than d ¼ 3, but toxicity-only methods cannot determine this. If the agent is ineffective for all doses, with true efficacy probabilities (0.00, 0.01, 0.01, 0.02, 0.02), the best decision is to not choose any dose, but toxicity-only methods still are most likely to choose d ¼ 3. Thus, ignoring efficacy when choosing a 'best' dose for future study or clinical practice is a bad idea.
Adding an expansion cohort following phase I also has several logical, scientific and ethical flaws. It is based on the fallacious assumption that the MTD is known reliably to be the 'best' dose, ignoring the fact that any estimate from a small sample has large uncertainty. Supplementary Figure S1 , available at Annals of Oncology online, shows 95% posterior credible intervals (CIs) for p T (MTD) in four cases, where [# toxicities]/[# patients treated] at the MTD are 1/6 (16%), 2/9 (22%), 2/12 (16%) or 3/15 (20%). The first 95% posterior CI says that, given one toxicity in six patients at the MTD, the probability is 0.95 that 0.007 < p T (MTD) < 0.52. Based on the 95% CIs, all four cases are consistent with p T (MTD) between 0.10 and 0.40.
In practice, treating an expansion cohort at a chosen MTD can be very problematic. Additional toxicity data easily may contradict the earlier conclusion that the selected dose is the MTD. Recently, sizes of expansion cohorts have exploded, with hundreds in some protocols [9] . A large 'phase I expansion cohort' actually is a phase II trial, but conducted without any design, other than a specified sample size. This practice magnifies all of the above problems with a small expansion cohort. The MTD easily may turn out to be too toxic or ineffective. If no efficacy events are seen at the MTD in phase I or in the first 30 patients of a 100 patient expansion cohort, should 70 more patients be treated? If phase I is followed by a phase II trial with stopping rules for both toxicity and efficacy, and is stopped due to excessive toxicity at the MTD, then the agent must be abandoned, or a second dose-finding trial may be conducted to find a safe lower dose. How should data from the two previous trials be used when designing such a third trial?
Methods-phase I-II trial design
The above problems with conventional methods are avoided by phase I-II designs [3] [4] [5] , which combine phase I and phase II into one trial. When a phase I-II trial is completed, no subsequent phase II trial is needed, since efficacy has been evaluated. The main components of a phase I-II design are summarized in Figure 1 and Box 1. A phase I-II design adaptively uses the (dose, efficacy, toxicity) data from all previous patients to make decisions and select the best dose for each new cohort. There is no 'hard' switch from toxicity-based phase I to cohort expansion or phase II.
Using toxicity and efficacy gives phase I-II designs several important advantages. Compared with conventional phase I designs, phase I-II designs are more efficient, and reliably identify an optimal P2RD in terms of both safety and efficacy. Depending on the trial objectives, various strategies can be employed to choose doses [3] . One approach sets a fixed upper limit A T on p T (d) and defines the dose with p T (d) < A T that maximizes p E (d) to be optimal. Another approach uses an efficacy-toxicity tradeoff to quantify each dose's desirability, and thus choose the optimal dose. To illustrate phase I-II designs, we use the EffTox design [5, 6] , which has been used to conduct several trials [7] [8] [9] . EffTox requires the investigator to specify a fixed A T and a fixed lower bound A E on p E (d), and uses an efficacy-toxicity trade-off contour as a criterion to choose each cohort's optimal dose. A dose d is acceptable if, given the current data, there are reasonably high posterior probabilities that
Values of A E and A T are determined by the clinical investigators, to reflect the particular definitions of efficacy and toxicity. Only acceptable doses are given to patients. If all doses are unacceptable the trial is stopped with no dose selected. Figure 2 gives the efficacy-toxicity trade-off contours for a particular EffTox design. All (p T , p E ) pairs on each contour are equally desirable. The desirabilities of the contours increase moving from upper left to lower right, as p T becomes smaller and p E becomes larger. A procedure for constructing trade-off contours is given in supplementary Data, available at Annals of Oncology online. An alternative phase I-II design is based on elicited utilities of the four possible (efficacy, toxicity) outcomes [10] [11] [12] .
During the trial, to choose each cohort's dose, the posterior means of p E (d) and p T (d) are computed for each acceptable d. The contour of this pair is determined, and the desirability of d is the desirability of the contour. The acceptable d with largest desirability is chosen for the next cohort. At the end of the trial, the dose with largest desirability is chosen as RP2D. Graphical user interface-based software for implementing EffTox is available at https://biostatistics.mdanderson.org/softwaredownload/.
By replacing separate phase I and II trials, a phase I-II trial can have a larger sample size than a conventional phase I trial. Using all (dose, efficacy, toxicity) data is much more informative than using only (dose, toxicity) data. If toxicity is too high or efficacy is too low for some d, the acceptability rules reduce the number of patients treated at d. If no dose is acceptable, the phase I-II design is likely to stop the trial early with no dose chosen.
In summary, advantages of phase I-II designs are that they (i) account explicitly for risk-benefit trade-offs between toxicity and efficacy; (ii) identify the optimal RP2D more reliably by using all (dose, efficacy, toxicity) data; (iii) avoid ad hoc dose modifications; and (iv) replace separate phase I and phase II trials with one trial.
Methods-illustrative trial
We illustrate EffTox using a trial conducted at the MD Anderson Cancer Center, using a disguised version for confidentiality. Five doses of lenalidomide were considered, 25, 50, 75, 100 and 125 mg/m 2 (d ¼ 1, 2, 3, 4, and 5), combined with a fixed dose of IV melphalan, as a preparative regimen for autologous stem cell transplant for myeloma. Toxicity was defined as regimen-related death, graft failure, or grade 3, 4 atrial fibrillation, deep venous thrombosis, or pulmonary embolism within 30 days post-transplant. Efficacy was defined as being alive and in complete remission at day 30. The fixed limits were A T ¼ 0.30, A E ¼ 0.20, the trade-off contours are illustrated in Figure 2 , N ¼ 30, cohort size 3, and no untried dose was skipped when escalating. Figure S2 , available at Annals of Oncology online, shows how the design adaptively adjusts its dose desirability estimates. After 10 cohorts at N ¼ 30, d ¼ 3 is the optimal P2RD, with estimated posterior mean toxicity probability 0.23, efficacy probability 0.63 and desirability 0.70. Totals of 3 patients were treated at d ¼ 1, 9 patients at d ¼ 2 and 18 patients at d ¼ 3. If the 3 þ 3 design were used instead, d ¼ 2 would be selected as the MTD/P2RD, where 0 of 9 patients achieved efficacy.
Methods-simulation study
We present a simulation study comparing EffTox with the 3 þ 3 algorithm and CRM with target p* ¼ 0.20, for a trial with five doses, maximum N ¼ 30 or 60 patients, and cohort size 3. Figure 1 . Diagram of phase I-II trial design. Based on the most recent data, the optimal dose is defined as the dose that maximizes the efficacy-toxicity trade-off. 1. Toxicity and efficacy outcomes that characterize potential risks and benefits of the treatment being studied 2. Risk-benefit trade-off criterion that characterizes and quantifies the trade-off between efficacy and toxicity for each dose 3. Statistical model describing the dose-toxicity and doseefficacy relationships 4. Adaptive decision rule that determines the best dose for the next cohort, based on the (dose, toxicity, efficacy) data from all previous patients 5. Admissibility rules that protect patients in the trial from unacceptably toxic or inefficacious doses 6. Stopping rule that terminates the trial early if the all doses being considered are unacceptably toxic or inefficacious
We included a modified CRM with cohort expansion (CRM-CE), using N/2 patients to find the MTD and N/2 as an expansion cohort. The CRM and CRM-CE include an early stopping rule if p T (d 1 ) > 0.20 is likely. For the 3 þ 3, after the MTD is selected, an expansion cohort is treated at the MTD, so the total sample size is N, for comparability. 
Results
Simulation results are summarized in supplementary Tables S1 and S2, available at Annals of Oncology online. Figure 4A shows the percentage of correct decisions (PCDs), defined as the percentage of simulated trials where (i) the optimal dose is selected if it exists or (ii) no dose is selected if no dose is acceptable, for each design with N ¼ 30 or 60. Overall, EffTox has the highest PCD. In Scenarios 1 and 2, the MTD is not optimal: in Scenario 1, d ¼ 2 is optimal, but p T (3) is closest to 0.20; and in Scenario 2, d ¼ 3 is optimal, but p T (4) is closest to 0.20. Therefore, although the CRM has highest probability of selecting the MTD, i.e. the dose with p T (d) closest to p* ¼ 0.20, it performs poorly in finding the optimal dose in these two scenarios. When the dose with p T (d) closest to 0.20 is optimal, as in Scenario 3, the CRM performs well. In Scenario 4, where all doses are ineffective, the CRM and 3 þ 3 both have very low PCD because they ignore efficacy, while EffTox correctly stops the trial and selects no dose with PCD¼ 0.77 for N ¼ 30 and PCD ¼ 0.87 for N ¼ 60. Figure 4B gives average numbers of patients treated at the optimal dose. In Scenario 4, since no dose is optimal, this is the number of patients not treated in the trial due to early termination. EffTox outperforms both the CRM and 3 þ 3 design, with higher numbers of patients treated at the optimal dose. This suggests that EffTox is more ethical.
Discussion
Phase I-II trial designs provide a new paradigm for optimizing doses of new treatments. They explicitly reflect risk-benefit trade-offs, and avoid logical, scientific and ethical flaws of traditional phase I methods. Phase I-II designs reliably optimize dose in settings where the RP2D based on toxicity alone may have low efficacy or desirability.
One limitation of phase I-II design is that it assumes the same eligibility criteria throughout the trial. If eligibility criteria of phase I and phase II differ, then a phase I-II design cannot be used to replace the conventional approach. In addition, if efficacy takes a long time to evaluate, this may make adaptive decision making logistically difficult, although a phase I-II design for handling this issue exists [19] and has been used in three trials at M.D. Anderson Cancer Center. Phase I-II designs have been developed for more complicated settings, including trials with ordinal outcomes [13] , three binary outcomes [14] , time-toevent outcomes [15] , jointly optimizing two-agent combinations [16, 17] or dose and schedule [10, 18] , finding doses in two cycles [19] and optimizing subgroup-specific doses [12, 20] .
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